5 Questions with Stephanie M. Davis, Ph.D., Program Officer, National Heart, Lung, and Blood Institute

Published on :

“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region and beyond to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Stephanie M. Davis, Ph.D., Program Officer, National Heart, Lung, and Blood Institute. Stay tuned for more interviews with others from across the BioHealth Capital Region and beyond.

Rockville’s Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease

Published on :

Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease (MVD). MVD is caused by either of two marburgviruses, Marburg virus and Ravn virus, and has reemerged several times since it was initially described in 1967. IBT-T03H, discovered in collaboration with the University of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.

NIH NCI Building T30 Cell Processing Modular Facility

TIL Cell Processing Modular Facility
Published on :

The Tumor-Infiltrating Lymphocytes (TIL) Cell Processing Modular Facility is the first large-scale, fully prefabricated and modular multi-module cGMP manufacturing facility of its kind ever built in the United States. The National Cancer Institute (NCI) will utilize the facility to deliver cutting-edge cancer treatment.